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Abstract 
OBJECTIVES 
To determine whether genetically raised fasting glucose (FG) level is associated with elevated 
blood pressure (BP) in healthy children and adolescents. 
DESIGN AND METHODS 
We used 14 common genetic variants of fasting glucose discovered in genome-wide association 
studies, including the rs560887 SNP located in the G6PC2 locus found to be robustly associated 
with FG in children and adolescents, as an instrument to associate FG with resting BP in 1,642 
children and adolescents from the European Youth Heart Study (EYHS).  
RESULTS 
Rs560887 was associated with increased FG levels corresponding to an increase of 0.09 mmol/l (P 
= 4.0 × 10-10). FG was associated with elevated BP, independent of other important determinants of 
BP in conventional multivariable analysis [systolic BP z-score: 0.32 SD per increase in mmol/l 
(95% CI 0.20-0.43, P = 5.4 × 10-8), diastolic BP z-score: 0.14 per increase in mmol/l (95% CI 0.07-
0.22, P = 3.5 × 10-4)]. This association was not supported by the Mendelian randomization 
approach, either from instrumenting FG from all 14 variants nor from the rs560887, where non-
significant associations of glucose with BP were observed.  
CONCLUSIONS 
The results of this study could not support a causal association between FG and BP in healthy 
children and adolescents; however it is possible that rs560887 has pleiotropic effects on unknown 
factors with a BP lowering effect or that these results were due to lack of statistical power.  
KEYWORDS 
Glucose, hyperglycemia, blood pressure, hypertension, Mendelian randomization, children. 
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Introduction 
Observational studies in children and adolescents have revealed a positive association between 
fasting glucose (FG) and blood pressure (BP) [1, 2]. Ten percent of adolescents with type 2 diabetes 
participating in the TODAY trial had hypertension, and the incidence during the average 3.9 years 
of follow-up was 22 percent [3]. Nevertheless, treatment with hypoglycemic agents could not lower 
the incidence of hypertension, and glycemic control was unrelated to the incidence of hypertension 
in this cohort of adolescents with type 2 diabetes [4]. In adults higher FG has been found to be 
associated with subsequent elevated BP in several prospective cohort studies [5-7]. However, some 
prospective studies do not support this association [8, 9] and as impaired FG and raised BP share 
common environmental and biological risk factors, residual and unknown confounding may explain 
the observed associations raising the possibility that hyperglycemia is not causally related to high 
BP. 
Some evidence from randomized controlled trials among type 1 diabetics and 
individuals with impaired glucose metabolism support a causal role for glucose homeostasis in risk 
of elevated BP. One trial has shown that intensive insulin therapy reduces the long-term risk of 
hypertension in patients with type 1 diabetes [10] and a second that glucose-lowering therapy in 
patients with impaired glucose tolerance is effective in reducing the risk of hypertension [11]. 
Because hypoglycemic agents also target pathways extrinsic to that of glucose homeostasis, 
findings from these trials could also be explained by other biological factors. Further evidence 
regarding whether this association is causal would be valuable since it would point to potential 
interventions for reducing raised FG levels in those at risk of, as well as with, diabetes in order to 
prevent hypertension. 
                      Genome-wide association studies have identified several common genomic variants 
associated with fasting glucose (FG) [12]. These include a variant (rs560887) located within the 
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third intron of the G6PC2 locus. G6PC2 is particularly expressed in pancreatic beta cells. G6PC2 is 
thought to hydrolyze glucose-6-phosphate (G6P) to glucose and inorganic phosphate opposing the 
action of glucokinase (a glucose sensor in beta cells) which facilitates phosphorylation of glucose to 
G6P in the first step of glycolysis [13]. The risk allele of rs560887 is believed to increase the 
expression or functional activity of G6PC2 [14]. As a consequence the flux of glucose into the 
glycolytic pathway is reduced and this may lead to a higher glucostatic set-point of the beta cell, 
possibly leading to a higher FG level as revealed in a recent report from the European Youth Heart 
Study (EYHS) [15]. The effect of this variant has been replicated and found to be robust in children 
and youth, [15, 16] as well as adults [14, 17, 18]. Importantly, there is currently no evidence 
showing that rs560887 has an effect on insulin levels, insulin sensitivity, or other biological 
parameters [12, 14-16], and with no obvious direct role of G6PC2 in a BP regulating pathway [12], 
this variant is an attractive instrument variable for FG. We therefore aimed to examine the 
association of FG with BP using conventional multivariable adjusted linear regression and also to 
examine the causal effect via a Mendelian randomization approach [19] by utilizing the common 
variant rs560887 in the G6PC2 gene and other confirmed FG variants from GWAS as instrumental 
variables (IV) for FG. We studied this in a population sample of healthy children and adolescent 
from the EYHS. 
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Methods 
Study population 
Data from the EYHS, a multi-country longitudinal population-based study in children, were used in 
this study. Details of the design and data collection for EYHS have been previously published [20]. 
DNA, relevant risk factors and outcome data were available from Estonian (city and county of 
Tartu) and Danish (city of Odense) participants. A proportional two-stage cluster sample of boys 
and girls aged 9-11 and 14–16 years were selected. In total, 2,025 children and adolescents agreed 
to participate, with a similar proportion participating in each country (76% accepted in Estonia and 
75% accepted in Denmark). A total of 1,660 had DNA samples available and full data on all 
variables. Additionally 15 individuals were excluded due to glucose levels ≥ 7mmol/l (n = 3) or not 
fasting overnight (n =15) leaving a total of 1,642 individuals.  
  
Anthropometry and maturity 
Weight, height and waist circumference (WC) were measured while the participants were wearing 
light clothing, without shoes, using standard techniques [20]. Body-mass index (BMI) was 
calculated as weight (kg)/height2 (m2). Waist circumference was measured with a metal 
anthropometric tape midway between the lower rib margin and the iliac crest at the end of gentle 
expiration. Pubertal status was assessed according to Tanner [21]. Assessment in girls was 
performed according to breast development and in boys according to pubic hair growth. Maturity 
stage among the 8-10-year olds was almost exclusively stage 1 or 2 in both Danish and Estonian 
children and almost all adolescents were categorized as Tanner stage 3, 4 or 5. Thus, we collapsed 
maturity to a 3-point ordinal variable (Tanner 1-2, Tanner 3-4, and Tanner 5). 
  
Fasting glucose, insulin and lipids 
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Intravenous blood samples were drawn from an antecubital vein after participants had fasted for at 
least 8 hours. These were separated and stored at -80°C until analysis. Blood samples were 
analyzed by one of two Clinical Pathology Accreditation (CPA) accredited laboratory located in 
Bristol or Cambridge, England. Glucose, high-density lipoprotein (HDL), total cholesterol (TC) and 
triglyceride (TG) concentrations were measured by standard methods using Olympus AU600 
random access analyzers. Insulin was analyzed using an enzyme immunoassay (microtiter plate 
format; Dako Diagnostics, Ely, U.K.). Between- laboratories correlations were 0.94–0.98 for 30 
randomly selected samples analyzed in both Bristol and Cambridge. 
  
Genotyping 
The selected 16 variants (loci) associated with FG were identified from published meta-analyses 
[12, 16]: rs4607517 (GCK), rs340874 (PROX1), rs11920090 (SLC2A2), rs11605924 (CRY2), 
rs560887 (G6PC2), rs780094 (GCKR), rs10885122 (ADRA2A), rs10830963 (MTNR1B), rs2191349 
(DGKB-TMEM195), rs7944584 (MADD), rs7034200 (GLIS3), rs13266634 (SLC30A8), rs11708067 
(ADCY5), rs174550 (FADS1), rs11071657 (C2CD4B), rs7903146 (TCF7L2). All of the SNPs were 
genotyped at the Medical Research Centre Epidemiology Unit Research Laboratory in Cambridge, 
England, using the TaqMan SNP Genotyping Assays (Applied Biosystems, Warrington, U.K.). The 
genotyping assay was undertaken on 10 ng of genomic DNA in a 5 μl 384-well TaqMan assay 
using a PTC-225 Thermal Cycler (MJ Research, Watertown, MA). The ABI PRISM 7900HT 
Sequence Detection System (Applied Biosystems, Warrington, U.K.) was used for end point 
detection and allele calling. The call rate was >98.9% and concordance of 44 duplicate samples was 
100%. 
  
Blood pressure 
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BP was measured with participants in the up-right sitting position after resting for five minutes. 
Five measurements were conducted with two minutes intervals between each (Dinamap model XL, 
Kivex/Critikron, Inc., Tampa, FL). The mean of the last three measurements was used in all 
analyses. The Dinamap monitor has been validated in children against direct radial artery readings 
(mean error 0.24 mmHg SBP, 1.28 mmHg DBP) [22]. BP measurements were converted to age-, 
height- and sex-specific z-scores according to National High Blood Pressure Education Program 
(NHBPEP) Working Group on Children and Adolescents [23]. 
  
Other covariates 
Parental educational level, birth weight, and infant breastfeeding status were obtained through a 
parental questionnaire. Breastfeeding status was, as previously described [24], expressed in a 
variable with two categories based on the mother’s response: i) children who were ever exclusively 
breastfed and ii) those whose mothers indicated that they were never exclusively breastfed. Parental 
educational level was classified according to International Standard Classification of Education 
(ISCED) (UNESCO 1997). However, as the details obtained of the description of education was 
insufficient, the ISCED level 1 and 2 were collapsed to one group, level 3, 4 were grouped, and 
level 5, 6 and 7 were grouped as one in the analysis. We used the highest maternal- or paternal level 
of SES reported in the analysis. 
  
Statistics 
We used multivariable linear regression to first examine the association of FG with BP, adjusting 
for potential confounding by age, age group, gender, country, maturity, parental education, birth 
weight, breastfeeding, BMI, waist circumference, triglycerides, total cholesterol, HDL and insulin. 
We also assessed the size and precision of the coefficient of rs560887 (per allele) on BP changes 
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with additional adjustment for FG. We used linear regression to examine the association of 
individual instruments with FG, adjusting for age, age group, gender and country. We then 
undertook an instrumental variables regression to determine the causal association of FG with BP. 
The IV analysis was performed using a two-stage least squares regression and we compared results 
from the instrumental variable regression to that from the standard linear regression using the 
Durbin form of the Durbin-Wu-Hausman statistic [25]. To evaluate the strength and robustness of 
rs560887 and the GRS to instrument FG we calculated the first stage F-statistic from our 
instrumental variables analysis. An F-value>10 has been proposed as a cut point for evaluating 
sufficiently strong instruments in instrument variables regression [26]. We also examined whether 
rs560887 was associated with any of the observed confounders.  
Because we studied two populations with possible different ancestry we explored the 
possibility for population stratification by conducting the rs560887-FG association separately in 
each of the two populations and comparing the point estimates before pooling the data in a single 
analysis. This was done by testing the rs560887-by-country interaction on glucose and evaluating 
the point estimates for each country. A p-value below 0.1 was considered indication of interaction. 
In all analyses the genetic model used was per allele. All statistical analyses were performed in 
STATA 11.0 (STATA Corporation, College Station, TX).  
  
Genetic risk scores 
The unweighted genetic risk score (GRS) was calculated by adding the number of risk alleles 
divided by the number of SNPs, assuming that each allele has an equal effect. The weighted genetic 
risk score (wGRS) was created by applying weights representing the effect size each allele carries 
on FG (extracted from the Barker et al. meta-analysis in healthy children and adolescents) [16]. 
Linear regression was performed, assuming an increase in risk with the accumulation of risk alleles, 
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adjusted for the possible confounders. The IV analysis was performed as described for rs560887. 
None of the SNPs were associated with insulin in this study, however other studies report an effect 
on insulin secretion by GCKR [12] and MTNR1B [27] respectively. MTNR1B may also have a 
protective effect on change in glucose concentrations [17]. Thus, excluding these two SNPs resulted 
in a significant increase of the F-value for both GRS and wGRS, Supplementary Table 1, leading us 
to proceed with genetic risk scores consisting of a total of 14 SNPs.  
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 Results 
General characteristics by age group and gender are shown in Table 1. The frequency of the minor 
allele (MAF) of rs560887 was 29.73% and 31.01% in Danish and Estonian samples, respectively. 
Table 2 shows the association of FG and other potential BP determinants with BP. FG was 
positively associated with BP in the basic model controlling for age, age group, gender and country. 
The association somewhat attenuated, but remained statistically significant after including all other 
determinants of BP. Fasting insulin, TC, triglyceride, BMI, waist circumference, and birth weight 
were significantly associated with either SBP or DBP in multivariable adjusted analyses including 
all potential determinants of BP (Table 2). Supplementary Table 2 details the association of 
potential confounding factors with rs560887 and supplementary Table 3 lists associations of 
potential confounding factors with FG. None of the confounders were associated with rs560887. By 
contrast, all of the confounding variables, with a few exceptions (HDL, birth weight and parental 
education) were associated with glucose. 
 
Association between common genetic glucose variants and fasting glucose 
We observed a strong association between the rs560887 and FG (increase in mmol/l per allele = 
0.09, 95% CI 0.06 to 0.11, P = 4.0 × 10-10) adjusting for age, age group, gender and country. When 
adjusting for all confounders, there was a small increase in significance level (P = 2.5 × 10-11). The 
first stage f-statistics was 36.44 and rs560887 accounted for 2.2% of the variance in FG 
(unadjusted). The associations of individual variants with FG are listed in supplementary Table 4. 
There was no country specific association between rs560887 and FG (P = 0.26 for interaction). The 
increase in mmol/l FG per addition of risk allele was 0.07 (95% CI 0.03 to 0.11, P = 3.3 × 10-4) for 
Estonia and 0.10 (95% CI 0.06 to 0.14, P = 2.2 × 10-7) for Denmark, adjusting for age, age group 
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and gender. However, the instruments in Estonia were not strong (Supplementary Table 1), thus, 
sensitivity analyses were performed excluding Estonia in the IV regression analysis. 
 
Mendelian randomization approach for the association between glucose and blood pressure 
Rs560887 was negatively, and non-significantly associated with SBPz, decreasing SBPz by -0.05 
SD (95% CI -0.11 to 0.02, P = 0.17) per allele, adjusted for age, age group, country and gender. A 
similar association was found with the genetic risk scores, decreasing SBPz with -0.01 SD per 
increase in risk alleles (95% CI -0.03 to 0.01, P = 0.36) and (95% CI -0.02 to 0.01, P = 0.26) for 
GRS and wGRS respectively. After adjusting for glucose, the effect on BP augmented and the P-
value became significant for both rs560887 and wGRS, decreasing SBPz with -0.08 SD (per allele) 
(95% CI -0.15 to -0.02, P = 0.01) and -0.02 SD (95% CI -0.03 to -0.003, P = 0.02) respectively, but 
not for GRS, decreasing SBPz with -0.02 SD (95% CI -0.03 to 0.001, P = 0.07). 
Table 3 shows the results from the IV analyses and compares these with the results 
from the conventional multivariable regression analyses. Despite the positive association from the 
conventional FG-BP multivariable regression the IV analysis using rs560887, GRS and wGRS 
showed a negative non-significant association with SBPz. The estimates from the IV approach with 
rs560887 and wGRS on SBPz were significantly different from the conventional multivariable 
analysis (P value for difference <0.05), unlike the GRS. When excluding Estonia, the association 
from the IV analysis using rs560887 was significantly inversely associated with SBPz (P = 0.04), 
Table 4. When analyzing Estonia alone no significant association was found (results not shown). 
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Discussion 
We determined the association of FG and BP with the help of the rs560887 common allele in the 
G6PC2 locus and a genetic risk score consisting of 14 SNPs, previously shown to be associated 
with FG in adults [12], children and adolescents [15, 16]. In a population-sample of European 
children and adolescents, FG in the non-diabetic range was positively associated with SBPz and 
DBPz in multivariable analyses adjusted for major lifestyle-, socio-demographic- and biological 
determinants of FG, suggesting the association was not a consequence of known confounders. In 
contrast, genetically elevated FG, either instrumented from rs560887 or all FG SNPs did not show 
an association to BP. In fact we observed evidence that associations differed between conventional 
analyses and the Mendelian randomization approach. Collectively, our results from the Mendelian 
randomization approach could not confirm that FG is causally related to BP among healthy children 
and adolescent of European descent.  
  
Comparison with other studies 
Our findings from the conventional analysis is in line with previous observational studies in 
children and adolescents supporting a positive association between FG and BP, and with studies 
comparing BP levels between diabetic and non-diabetic children and adolescents [1, 2, 28, 29]. 
Furthermore, the majority of previous observational studies among healthy adults suggest a positive 
association between FG and BP levels [5-7]. We are not aware of any studies that have reported 
associations of genetically elevated FG with BP levels or hypertension; however, other MR 
analyses describing associations of glucose levels and related outcomes have been reported. A 
recent study among Danish men and women found that genetically elevated non-fasting glucose 
levels was associated with an increased risk of coronary heart disease independent of hypertension 
and other biological CVD risk factors [30]. A study among US men and women found that a 
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genetic risk score based on five GWAS FG variants was associated with intima media thickness in 
the same direction as influencing FG, however, it was not reported whether BP explained this 
association. Although these studies suggest a causal effect of elevated glucose levels on 
development of atherosclerosis and coronary heart disease, further MR studies with BP or 
hypertension are warranted to further refute or support the notion that elevated glucose levels is 
causally related to raised BP levels. 
 
Limitations with Mendelian randomization 
Firstly, if the genetic determinants of FG have pleiotropic effects (exert effects on other factors that 
are related to BP regulation), our results could be biased. Thus, an alternative explanation for our 
observations could be that the rs560887 common allele increases FG levels as well as decreases BP. 
Because we did not find associations of rs560887 or the genetic risk score with any other major 
determinants of FG, we are fairly confident that this is not the case. Secondly, another limitation of 
Mendelian randomization approach is the use of weak instruments. The first stage F-statistics for 
rs560887 was high, confirming a strong instrument. Thirdly, population stratification could lead to 
spurious results. Sensitivity analyses confirmed that genetic effects of FG SNPs were fairly similar 
between countries and because both populations are of European descent and MAF was similar in 
both populations, the existence of population stratification is unlikely [19]. Lastly, our study could 
be insufficiently powered to determine valid results from the Mendelian randomization approach. 
 
Strengths of the study 
One of the strengths of this study is the use of a common variant robustly associated with FG. 
Further, no evidence of pleiotropy from our own investigations or other studies has been found. 
Another strength of this study is that the study population consists of individuals in the early stages 
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of life (healthy children and adolescents). Studies with an adult population may have a higher 
prevalence of preclinical diseases (due to accumulation of environmental and behavioral 
influences), potentially interfering with a possible causal association. However if the cumulative 
effect of common genetic glucose variants on FG adds up with time, there is a chance that we could 
detect effects of larger magnitude in an adult population, as suggested by Renstrom et al. [17].  
  
Conclusion 
Although conventional multivariable adjusted analyses showed that FG was positively associated 
with BP amongst healthy children and adolescents, this association could not be confirmed by the 
Mendelian randomization approach using either the common variant rs560887 in the G6PC2 locus 
or several FG SNPs jointly as instruments. Because, our study was moderate in size we cannot 
exclude that our finding was due to statistical power reasons and additional studies among 
populations of children, youth, and adults are needed to further exclude this possibility.  
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Table 1. Characteristics of the participants by age group and gender, n = 1,642 
 Children (n = 1,001)  Adolescents (n = 641) 
 Boys (n = 477) Girls (n = 524)  Boys (n = 
291) 
Girls (n = 
350) 
Age (years) 9.7 ± 0.4 9.6 ± 0.4   15.5 ± 0.5 15.4 ± 0.5 
Height (cm) 139.0 ± 6.7 138.8 ± 6.8  174.4 ± 7.2 165.0 ± 6.0 
Weight (kg) 33.1 ± 6.0 33.1 ± 6.9  62.9 ± 10.1 56.0 ± 8.4 
BMI (kg/m2) 17.1 ± 2.2 17.1 ± 2.6  20.6 ± 2.6 20.5 ± 2.7 
Waist circumference (cm) 59.4 ± 5.4 58.4 ± 6.7  71.5 ± 6.0 66.7 ± 5.9 
Maturity*- No (%)      
1 477 (100.00) 513 (97.9)  11 (3.8) 2 (0.6) 
2 - 11 (2.1)  127 (43.6) 191 (54.6) 
3 - -  153 (52.6) 157 (44.9) 
SBP (mm Hg) 102.6 ± 8.9 101.0 ± 8.7  115.9 ± 11.3 107.7 ± 9.4 
SBPz 0.02 ± 0.8 -0.10 ± 0.8  -0.03 ± 1.0 -0.62 ± 0.9 
DBP (mm Hg) 60.0 ± 7.1 60.0 ± 6.5  63.0 ± 6.8 64.0 ± 6.6 
DBPz -0.10 ± 0.6 -0.06 ± 0.6  -0.23 ± 0.6 -0.22 ± 0.6 
Glucose (mmol/l) 5.1 ± 0.4 5.0 ± 0.4  5.2 ± 0.4 5.0 ± 0.4 
Insulin (pmol/l) 39.7 ± 22.0 46.4 ± 24.6  70.6 ± 36.1 78.2 ± 37.0 
TC (mmol/l) 4.4 ± 0.7 4.6 ± 0.8  4.0 ± 0.7 4.4 ± 0.8 
HDL (mmol/l) 1.6 ± 0.4 1.5 ± 0.3  1.3 ± 0.3 1.4 ± 0.3 
Triglycerides (mmol/l) 0.7 ± 0.3 0.8 ± 0.3  0.8 ± 0.3 0.9 ± 0.4 
Birth weight (g) 3519 ± 626 3413 ± 602  3528 ± 591 3323 ± 549 
Breastfeeding- No (%) 406 (85.1) 453 (86.5)  242 (83.2) 269 (77.9) 
Parental education**- No (%)      
1 31 (6.50) 26 (5.0)  16 (5.5) 31 (8.9) 
2 120 (25.2) 137 (26.2)  73 (25.1) 83 (23.7) 
3 326 (68.3) 361 (68.9)  204 (69.4) 237 (67.4) 
Unweighted risk score (GRS) 18.2 ± 2.3 18.2 ± 2.5  18.1 ± 2.2 18.3 ± 2.2 
Weighted risk score (wGRS) 20.7 ± 3.0 20.7 ± 3.1  20.6 ± 3.1 21.0 ± 3.0 
 
Data are means ±SD or %. BMI= body mass index, SBP= systolic blood pressure, DBP= diastolic 
blood pressure, TC= total cholesterol, HDL= high-density lipoprotein cholesterol. 
*Maturity 1= Tanner stage 1-2, Maturity 2= Tanner stage 3-4 and Maturity 3= Tanner stage 5.  
** According to International Standard Classification of Education (ISCED) (UNESCO 1997). 
Parental education 1= ISCED level 1-2, Parental education 2= ISCED level 3-4 and Parental 
education 3= ISCED level 5-7. 
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Table 2. Associations of fasting glucose, and potential confounders, with blood pressure, n = 1,642  
 
Difference in SBPz per unit of category of 
exposure 
Difference in DBPz per unit of category of 
exposure 
 Effect size 95% CI P-value Effect size 95% CI P-value 
Glucose 
(mmol/l)a 0.40 0.28 ; 0.51 6.6 × 10-12 0.21 0.13 ; 0.28 1.5 × 10-7 
Insulin (pmol/l) a 0.01 0.004 ; 0.01 5.2 × 10-15 0.003 0.002 ; 0.004 1.4 × 10-8 
TC (mmol/l) a 0.13 0.07 ; 0.18 1.0 × 10-5 0.10 0.06 ; 0.13 8.4 × 10-7 
TG (mmol/l) a 0.40 0.28 ; 0.53 4.4 × 10-10 0.27 0.19 ; 0.36 3.2 × 10-10 
HDL (mmol/l ) a -0.08 -0.21 ; 0.06 0.26 0.002 -0.09 ; 0.09 0.96 
BMI (kg/m2) a 0.08 0.06 ; 0.10 1.5 × 10-20 -0.002 0.00 ; 0.02 0.12 
WC (cm) a 0.02 0.02 ; 0.03 1.2 × 10-11 -0.001 -0.01 ; 0.004 0.60 
Birth weight (g) 
a -1.1 × 10-4 
-1.9 × 10-4 ;  
-4.3 × 10-5 0.002 1.6 × 10-5 
-6.4 × 10-5 ; 
 3.3 × 10-5 0.52 
Glucose 
(mmol/l)b 0.32 0.20 ; 0.43 5.4 × 10-8 0.14 0.07 ; 0.22 3.5 × 10-4 
Insulin (pmol/l) 
b 1.8 × 10-3 
2.7 × 10-4 ; 
3.4 × 10-3 0.02 1.5 × 10-3 
4.5 × 10-4;  
2.6 × 10-3 5.0 × 10-3 
TC (mmol/l) b 0.08 0.02 ; 0.15 0.01 0.07 0.02 ; 0.11 3.0 × 10-3 
TG (mmol/l) b 0.12 -0.01 ; 0.26 0.10 0.16 0.06 ; 0.25 1.9 × 10-3 
HDL (mmol/l) b -0.04 -0.20 ; 0.11 0.60 -0.02 -0.12 ; 0.09 0.77 
BMI (kg/m2) b 0.08 0.05 ; 0.11 7.2 × 10-8 0.02 5.5 × 10-5 ; 0.04 0.049 
WC (cm) b -0.01 -0.02 ; 0.01 0.26 -0.01 
-0.02 ;  
-4.7 × 10-3 2.5 × 10-3 
Birth weight b 
(g) 1.4 × 10-4 
2.1 × 10-4 ;  
6.7 × 10-5 1.3 × 10-4 4.7 × 10-6 
4.4 × 10-5 ;  
5.3 × 10-5 0.85 
 Difference in SBPz by category Difference in DBPz by category 
Breast-fed a -0.17 -0.28;- 0.05 0.004 -0.05 -0.13 ; 0.02 0.17 
Maturity* a       
1 reference - - reference - - 
2 0.09 -0.27 ; 0.44 0.63 -0.09 -0.33 ; 0.15 0.48 
3 0.47 0.11 ; 0.84 0.01 0.13 -0.12 ; 0.38 0.29 
Parental edu** a       
1 reference - - reference - - 
2 -0.08 -0.27 ; 0.11 0.41 -0.06 -0.19 ; 0.07 0.36 
3 -0.14 -0.31 ; 0.04 0.14 -0.11 -0.23 ; 0.02 0.09 
Breast-fed b -0.14 -0.25 ; -0.03 0.01 -0.04 -0.11 ; 0.04 0.32 
Maturity* b       
1 reference - - reference - - 
2 -0.11 -0.45 ; 0.23 0.54 -0.10 -0.34 ; 0.14 0.41 
3 0.19 -0.16 ; 0.55 0.28 0.10 -0.15 ; 0.35 0.42 
Parental edu** b       
1 reference - - reference - - 
2 -0.08 -0.26 ; 0.10 0.39 -0.06 -0.18 ; 0.07 0.36 
3 -0.08 -0.25 ; 0.09 0.34 -0.09 -0.21 ; 0.03 0.16 
 
SBP=systolic blood pressure, DBP=diastolic blood pressure, TC=total cholesterol, TG=triglyceride, HDL=high-
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density lipoprotein cholesterol, BMI=body mass index, WC= waist circumference, edu= education.  
aAdjusted for country, age, age group, gender.  
bAdjusted for country, age, age group, gender, maturity, country, parental education, birth weight, breastfeeding, 
BMI, waist circumference, triglycerides, total cholesterol, HDL and insulin. 
*Maturity 1= Tanner stage 1-2, Maturity 2= Tanner stage 3-4 and Maturity 3= Tanner stage 5.  
** According to International Standard Classification of Education (ISCED) (UNESCO 1997). Parental 
education 1= ISCED level 1-2, Parental education 2= ISCED level 3-4 and Parental education 3= ISCED level 5-
7. 
Table 3. Instrumental variable analyses of the association of fasting glucose with blood pressure, using rs560887 and genetic risk scores, n = 1,642. 
 Difference in SBPz  per increase in mmol/l FG  Difference in DBPz per increase in mmol/l FG  
 Effect size 95% CI P-value 
P-value for 
difference with 
conventional 
approach* Effect size 95% CI P-value 
P-value for 
difference with 
conventional 
approach * 
IV analysis, 
rs560887a -0.52 -1.27 ; 0.22 0.17 
 
0.01 0.01 -0.49 ; 0.51 0.97 
 
0.43 
IV analysis, 
rs560887b -0.42 -1.13 ; 0.30 0.25 
 
0.03 4.9× 10-4 -0.49 ; 0.49 1.00 
 
0.47 
IV analysis, GRSa -0.43 -1.34 ; 0.49 0.36 
 
0.07 -0.01 -0.63 ; 0.60 0.97 
 
0.47 
IV analysis, GRSb -0.39 -1.26 ; 0.49 0.39 
 
0.11 -0.12 -0.72 ; 0.49 0.70 
 
0.38 
IV analysis, 
wGRSa -0.41 -1.13 ; 0.31 0.26 
 
0.02 -0.02 -0.50 ; 0.47 0.95 
 
0.33 
IV analysis, 
wGRSb -0.34 -1.03 ; 0.35 0.34 
 
0.04 0.10 -0.58 ; 0.37 0.67 
 
0.25 
MV analysisa   0.40 0.28 ;  0.51 <0.0001    0.21 0.13 ; 0.28 <0.0001  
MV analysisb  0.32 0.20 ; 0.43 <0.0001  0.14 0.07 ; 0.22 <0.0001  
 
SBP=systolic blood pressure, DBP=diastolic blood pressure, FG= fasting glucose, CI= confidential interval, IV= instrumental variable, MV= multivariable, 
GRS= unweighted genetic risk score, wGRS= weighted genetic risk score.  
aAdjusted for country, age, age group, gender.  
bAdjusted for country, age, age group, gender, maturity, country, parental education, birth weight, breastfeeding, BMI, waist circumference, triglycerides, 
total cholesterol, HDL and insulin. * P-value for difference in estimates between results from the IV approach and the conventional approach (MV analysis), 
using Durbin-Wu Hausman 
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Table 4. Instrumental variable- and multivariable regression analyses of the association of fasting glucose with blood pressure, using rs560887 and genetic 
risk scores, excluding Estonia, n = 873. 
 
Difference in SBPz  per increase in  
mmol/l FG 
Difference in DBPz per increase in  
mmol/l FG 
 
Effect  
size 95% CI P-value 
P-value for 
difference with 
conventional 
approach* Effect size 95% CI P-value 
P-value for 
difference with 
conventional 
approach* 
IV analysis, 
rs560887a -0.77 -1.58 ; 0.05 0.07 
 
0.01 0.06 -0.51 ; 0.62 0.85 
 
0.44 
IV analysis, 
rs560887b -0.82 -1.58 ; -0.06 0.04 
  
0.03 -0.07 -0.62 ; 0.47 0.79 
 
0.47 
IV analysis, 
GRSa 0.01 -0.75 ; 0.77 0.98 
 
0.047 -0.18 -0.70 ; 0.34 0.50 
 
0.37 
IV analysis, 
GRSb -0.17 -0.89 ; 0.54 0.64 
  
0.11 -0.37 -0.88 ; 0.14 0.16 
  
0.38 
IV analysis, 
wGRSa -0.25 -0.90 ; 0.41 0.46 
 
0.01 0.00 -0.45 ; 0.45 1.0 
 
0.20 
IV analysis, 
wGRSb -0.35 -0.97 ; 0.27 0.27 
 
0.04 -0.18 -0.62 ; 0.26 0.43 
  
0.25 
MV analysisa 0.25 0.11 ; 0.39 0.001  0.16 0.06 ; 0.3 0.002  
MV analysisb  0.13 -0.01 ; 0.28 0.08  0.08 -0.02 ; 0.18 0.13  
 
SBP=systolic blood pressure, DBP=diastolic blood pressure, FG= fasting glucose, CI= confidential interval, IV= instrumental variable, MV= multivariable, 
GRS= unweighted genetic risk score, wGRS= weighted genetic risk score,  aAdjusted for country, age, age group, gender. bAdjusted for country, age, age 
group, gender, maturity, country, parental education, birth weight, breast-feeding, BMI, waist circumference, triglycerides, total cholesterol, HDL  and 
insulin. 
* P-value for difference in estimates between results from the IV approach and the conventional approach (MV analysis), using Durbin-Wu Hausman 
 
Supplementary Table 1. Association of rs560887, GRS and wGRS with FG, analyzed separately and 
jointly for countries, n = 1,642 
 Difference in FG per increase of risk allele 
 mmol/l 95% CI P-value F-value 
Denmark and Estonia, n = 1642 
Rs560887 0.09 0.06 ; 0.11 1.9 × 10-9 36.44 
GRS-16 0.01 0.01 ; 0.02 4.4 × 10-4 12.38 
wGRS-16 0.01 0.003 ; 0.02 0.003 8.65 
GRS-14 0.02 0.01 ; 0.03 9.7 × 10-7 24.17 
wGRS-14 0.02 0.01 ; 0.03 4.1 × 10-10 39.56 
Denmark,  n = 873 
Rs560887 0.10 0.06 ; 0.14 3.9 × 10-7 26.13 
GRS-16 0.02 0.01 ; 0.03 3.1 × 10-5 17.55 
wGRS-16 0.01 0.006 ; 0.02 0.001 12.03 
GRS-14 0.03 0.02 ; 0.04 5.5 × 10-8 30.06 
wGRS-14 0.03 0.02 ; 0.04 2.1 × 10-10 41.33 
Estonia, n = 769 
Rs560887 0.07 0.03 ; 0.11 8.3 × 10-4 11.27 
GRS-16 0.004 -0.01 ; 0.01 0.41 0.67 
wGRS-16 0.003 -0.005 ; 0.01 0.46 0.56 
GRS-14 0.01 -0.001 ; 0.02 0.08 3.05 
wGRS-14 0.01 0.004 ; 0.02 0.003 8.62 
 
Results are unadjusted estimates. GRS-16 and wGRS-16 include all 16 SNPs. GRS-14 and wGRS-14 
include 14 SNPs, after excluding the ones that influence insulin levels. GRS= unweighted genetic risk 
score, wGRS= weighted genetic risk score, FG= fasting glucose, CI= confidential interval.  
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Supplementary Table 2. Confounding variables association with rs560887, n = 1,642. 
Confounder ß 95% CI P-value 
Age (years) -0.1 -0.4 ; 0.06 0.17 
Height (cm) -0.6 -1.82 ; 0.61 0.33 
Weight (kg) -0.8 -1.9 ; 0.3 0.13 
BMI (kg/m2)  -0.2 -0.43 ; 0.02 0.07 
WC (cm) -0.5 -1.1 ; 0.05 0.07 
Insulin (pmol/l) -1.0 -3.4 ; 1.5 0.44 
Tc (mmol/l) -0.01 -0.06 ; 0.05 0.82 
TG (mmol/l) 0.01 -0.02 ; 0.04 0.46 
Hdl (mmol/l) -0.01 -0.04 ; 0.01 0.26 
Birth weight (g) -19.7 -63.9 ; 24.5 0.38 
Maturity - - 0.37* 
Breast-feeding - - 0.20* 
Parental education - - 0.05* 
 
Results are unadjusted estimates. *from chi2 test. CI= confidential interval, BMI=body mass index, WC= 
waist circumference, Tc=total cholesterol, TG=triglyceride, Hdl=high density lipoprotein cholesterol.  
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Supplementary Table 3. Confounding variables association with fasting glucose, n = 1,642. 
Confounder ß 95% CI P-value 
Age (years) 0.8 0.5 ; 1.2 <0.0001 
Height (cm) 6.8 4.7 ; 8.8 <0.0001 
Weight (kg) 5.8 3.9 ; 7.6 <0.0001 
BMI (kg/m2) 0.7 0.3 ; 1.1 <0.0001 
Waist (cm) 3.0 2.0 ; 4.0 <0.0001 
Insulin (pmol/l) 26.7 20.7 ; 28.7 <0.0001 
Tc (mmol/l) 0.1 0.01 ; 0.2 0.03 
TG (mmol/l) 0.1 0.1 ; 0.2 <0.0001 
Hdl (mmol/l) -0.002 -0.04 ; 0.04 0.93 
Birthweight (g) -6.6 -82.0 ; 68.8 0.86 
Maturity - - 0.003* 
Breast-feeding - - 0.003* 
Education - - 0.73* 
 
Results are unadjusted estimates. *from chi2 test. CI= confidential interval, BMI=body mass index, WC= 
waist circumference, Tc=total cholesterol, TG=triglyceride, Hdl=high density lipoprotein cholesterol. 
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Supplementary Table 4. Associations of the individual SNPs from our study, with 
fasting glucose, n = 1,642. 
SNP (locus) Effect size 95% CI P-value 
rs4607517 (GCK) -0.02 -0.06 ; 0.02 0.33 
rs340874 (PROX1) 0.02 -0.01 ; 0.04 0.23 
rs11920090 (SLC2A2)  0.04 0.01 ; 0.08 0.02 
rs11605924 (CRY2) 0.00 -0.02 ; 0.03 0.87 
rs560887 (G6PC2)  0.09 0.06 ; 0.11 <0.0001 
rs10885122 (ADRA2A)  0.03 0.00 ; 0.07 0.08 
rs2191349 (DGKB-TMEM195)  0.00 -0.02 ; 0.03 0.71 
rs7944584 (MADD) 0.04 0.01 ; 0.07 0.01 
rs7034200 (GLIS3)  0.01 -0.02 ; 0.03 0.56 
rs13266634 (SLC30A8)  0.04 0.01 ; 0.06 0.01 
rs11708067 (ADCY5) 0.03 0.00 ; 0.06 <0.05 
rs174550 (FADS1) 0.00 -0.02 ; 0.03 0.85 
rs11071657 (C2CD4B) 0.01 -0.01 ; 0.04 0.35 
rs7903146 (TCF7L2)  -0.01 -0.04 ; 0.02 0.33 
 
Country, age, age group and gender adjusted. CI= confidential interval. 
 
 
 
